An Update in Drug-Induced Thrombotic Microangiopathy

Frontiers in Medicine

article

Thomas Chatzikonstantinou¹  Maria Gavriilaki²  Achilles Anagnostopoulos¹  Eleni Gavriilaki¹ 

[1] BMT Unit, Hematology Department, G Papanicolaou Hospital;Laboratory of Clinical Neurophysiology, AHEPA Hospital, Aristotle University of Thessaloniki

关键词: thrombotic microangiopathy;    drug;    hematology;    oncology;    neurology;   

DOI  :  10.3389/fmed.2020.00212

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Drug-induced thrombotic microangiopathy (DITMA) is a life-threatening complication that is often under-recognized and under-reported (1). Despite recent systematic reviews published in 2015 (2) and 2018 (3), the list of drugs implicated in TMA continues to expand (4–9). In addition, novel reports have unraveled potential new mechanisms that might contribute to a targeted therapy of this syndrome. In this opinion article, we aimed to summarize recent data on DITMA, categorizing drugs based on mechanisms of actions and specialties.

【 授权许可】

CC BY